Fraunhofer Institute for Toxicology and Experimental Medicine

What turns cells into killer cells?

Our Regensburg-based Division of Personalized Tumor Therapy is searching for approaches for novel diagnostics and personalized treatments in the fight against cancer.

more info

Accelerated production of a passive vaccine against COVID-19

Fraunhofer ITEM and Corat Therapeutics GmbH are beginning production of a specific SARS-CoV-2 antibody.

more info

Medical research on SARS-CoV-2

With our decades of experience in infection and airway research, drug development, biomedical engineering, and in the field of chemical risk assessment, we are meanwhile involved in numerous projects to fight the COVID-19 pandemic.

more info

Safety first!

Despite short-term authorization of certain disinfectants by way of exception, safety and efficacy are top priority.

more info

Finding a drug against corona

Interview with Prof. Armin Braun and Prof. Mark von Itzstein regarding the enhancement of the German-Australian iCAIR® project to include the coronavirus SARS-CoV-2.

more info

EU project MDOT

Development of an open-innovation test bed to support small and medium-sized manufacturers of medical devices in the conformity assessment of their products.

more info

Bioinformatics and Digital Health

Processing large quantities of data is a major challenge of our era, in the life sciences in particular. The Project Group for Bioinformatics has been set up as an “Attract Group” at Fraunhofer ITEM.

more info

Respiratory infections

Fraunhofer ITEM research teams are facing up to the challenges in infection research. Dr. Sabine Wronski, manager of the Working Group on Infection and Immunology, talks about this in an interview.

more info

Fighting bacteria with viruses

Fraunhofer scientists have joined forces with partners in the Phage4Cure project to explore alternatives to antibiotics.

more info

Replacing animal testing

Fraunhofer ITEM advances the development of new-approach methodologies. Our scientists Dr. Sylvia Escher and Dr. Tanja Hansen discussed the paradigm shift in chemical risk assessment.

more info

Fraunhofer ITEM: News


Press Release / 19.10.2020

BEAT-COVID - advanced therapy strategies

Fraunhofer consortium to jointly develop therapies and platform technologies against COVID-19 and other infectious diseases.

News / 12.10.2020

Drug repurposing project DRECOR

Identification of drugs against COVID-19 and development of therapies.


Press Release / 6.10.2020

Publication in “Nature Communications“

Disseminated breast cancer cells use bone marrow growth factors for metastasis formation.

News / 23.9.2020

Metabolomics research

Quantitative targeted metabolomics, with a focus on a subset of hundreds of metabolites, is a valuable tool to study possible underlying mechanisms.

News / 6.10.2020

Nature Reviews Cancer

New publication by Christoph A. Klein: „Cancer progression and the invisible phase of metastatic colonization”.

News / 18.8.2020

"Production for Intelligent Medicine"

Fraunhofer innovation cluster relies on automation technologies in medical research.

Our services and expertise

Pioneers for sustainable health

Research at Fraunhofer ITEM is focused on human health – and this has been so for almost four decades.

The emphasis is on two aspects: firstly, on protecting health from potentially harmful, in particular airborne substances, be they gases, aerosols, particles, fibers, or nanomaterials, and secondly, on investigating and developing diagnostic and therapeutic approaches, both at the preclinical and clinical levels.

A special focus is on airway research.


Chemical Safety and Assessment


Translational Biomedical Engineering


Personalized Tumor Therapy

Focus of our research

The lung and airways are at the focus of our R&D activities. Furthermore, Fraunhofer ITEM engages in the development and manufacturing of biopharmaceuticals, tumor therapy, and translational biomedical engineering.


Bioinformatics and Digital Health

The Project Group for Bioinformatics improves the analysis of data collected in health research by using novel intelligent methods.


Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Nikolai-Fuchs-Strasse 1
30625 Hannover

Phone +49 511 5350-0



Training course: In-silico toxicology

This training course will introduce the participants to three different in-silico approaches for estimation of human health toxicological endpoints, namely QSAR models, read-across, and the TTC (threshold of toxicological concern) concept. The application of in-silico approaches in ecotoxicology will not be addressed in this course.
Read more


International Symposium »Experimental Medicine in Lung Disease«

This symposium has been CANCELED! In view of the ongoing worldwide COVID-19 pandemic, we have reluctantly decided to cancel the symposium originally scheduled for November 12th and 13th, 2020.
Read more


Immunology Day 2020

On "Immunology Day“, current topics in the field of immune-mediated diseases will be presented and discussed across disciplines and across institute borders. The aim is to review current challenges and jointly develop novel approaches. “Immunology Day” is intended to serve as an information and exchange platform and to contribute to the advancement of immune research by pooling expertise.
Read more


ERS International Congress 2020

The International Congress 2020 of the European Respiratory Society will be held as an interactive and virtual event from September 7 to 9, 2020. Fraunhofer ITEM will actively contribute to the program of this event – with a poster presentation, an oral presentation, and a poster session chair.
Read more

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 74 institutions of the Fraunhofer-Gesellschaft, Europe's leading organization for applied research. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on airway research, our R&D portfolio includes three thematic areas: drug development, chemical safety, and translational biomedical engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of 357 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.

More information about Fraunhofer ITEM